Enzyme-responsive hybrid prodrug of nitric oxide and hydrogen sulfide for heart failure therapy

A hybrid prodrug was synthesized to realize the combined delivery of nitric oxide and hydrogen sulfide. The NO–H2S donor can release nitric oxide and hydrogen sulfide step by step in response to the endogenous enzymes β-galactosidase and carbonic anhydrase, providing potent therapeutic efficacy for heart failure post- myocardial infarction.